TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Home Education and Support Trial (CHEST): A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (patients): Men and women who~* are having first-time non-emergency CABG surgery~* are judged ready for discharge~* are being discharged to home \[either their own or to family/friends\]~* have access to and are able to communicate over a telephone~* are able to read, write and understand English~Inclusion Criteria (peers): Men and women who~* have undergone CABG surgery within the last 5 years~* have access to and are able to communicate clearly over a telephone~* are able to read, write and understand English~* have attended a formal cardiac rehabilitation program~* are not associated with the current in-hospital peer volunteer program

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years or between the ages of 60 and 85 years, inclusive.~* Body Mass Index (BMI) of 17.5 to 32 kg/m2; and a total body weight \>50 kg (110 lbs) at Screening.~* Evidence of a personally signed and dated informed consent document indicating that the subject or a legally acceptable representative has been informed of all pertinent aspects of the study.~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).~* Male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.~* Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol.~* Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.~* Any severe acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Single Ascending Dose Cross-over (Type: EXPERIMENTAL): Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
- Multiple Ascending Dose PF-06751979 (Type: EXPERIMENTAL): Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
- Multiple Ascending Dose Placebo (Type: PLACEBO_COMPARATOR): Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
- Multiple Dose Elderly PF-06751979 (Type: EXPERIMENTAL): Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
- Multiple Dose Elderly Placebo (Type: PLACEBO_COMPARATOR): Multiple dose administration to Healthy Elderly Subjects (Placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants ≥ 18 years of age.~* Histologically or cytologically documented breast cancer.~* Metastatic or unresectable locally advanced/recurrent breast cancer.~* HER2-positive disease by prospective laboratory confirmation.~* Disease progression on the last regimen received as defined by the investigator.~* Prior treatment with an trastuzumab, a taxane, and lapatinib.~* Disease progression after at least two regimens of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.~* Adequate organ function, as evidenced by laboratory results.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.~* Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multi gated acquisition scan.~Exclusion Criteria:~* Chemotherapy ≤ 21 days before first study treatment.~* Trastuzumab ≤ 21 days before first study treatment.~* Lapatinib ≤ 14 days before first study treatment.~* Prior enrollment in a trastuzumab emtansine containing study, regardless whether the patient received prior trastuzumab emtansine.~* Brain metastases that are untreated or symptomatic, or require any radiation, surgery or corticosteroid therapy to control symptoms within 1 month of randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab emtansine (Type: EXPERIMENTAL): Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
- Treatment of physician's choice (Type: ACTIVE_COMPARATOR): Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple sclerosis (MS)~* Relapsing MS (RMS)~* At least 1 appearance of a new neurological abnormality or worsening of pre-existing neurological abnormality during the previous 2 years prior to Screening AND an MRI activity (Gd-enhancing T1 lesions or new or enlarging T2 lesions) in brain during the previous 1 year prior to randomization~* EDSS score of 0 to 5.5~Exclusion Criteria:~* Primary progressive MS or SPMS without disease activity~* Patients with an active chronic disease of the immune system other than MS~* Patients at risk of developing or having reactivation of hepatitis~* Patients with active systemic infections or with neurological findings consistent with PML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- OMB 20 mg (Type: EXPERIMENTAL): Ofatumumab 20 mg subcutaneous injection on Days 1,7, 14 and every 4 weeks for 24 weeks in Core. Core placebo patients received loading dose at Weeks 25 and 26 and then all Extension patients received dose every 4 Weeks up to Week 48.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks in Core

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Application of n-3 Fatty to Patient of Jaundice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* the diagnosis of obstructive jaundice must be clear (serum toal bilirubin \>51.3umol/L \& Imaging evidence), and the obstruction is located in the extrahepatic bile duct;~* Duration of Jaundice is less than 2 weeks;~* Nutritional support is needed~* Nutritional support was administrated during the perioperative period;~* Drainage treatment is effective.~Exclusion Criteria:~* Contraindication for surgical procedure, including Child-Pugh Classification C, severe hemorrhagic disorders, gastrointestinal hemorrhage, acute infectious disease, active phase of chronic hepatitis B \& C, severe circulatory disease, renal failure pre -operation, and other unknown cause;~* Abandon treatment;~* Length of stay in hospital \<5 day;~* Nutrition support \<5 day;~* Conservative treatment;~* Incomplete data;~* Allergic reactions against PN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- trail cohort (Type: None): n-3 FAs
- control cohort (Type: None): Structolipid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with locally advanced, recurrent or metastatic histologically confirmed malignancy refractory to available standard treatment~Exclusion Criteria:~* Prior treatment with Lapatinib, Sorafenib or any agents targeting EGFR (other than trastuzumab), Raf, VEGF, or VEGFR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib and Sorafenib 1° level of dose (Type: EXPERIMENTAL): Lapatinib 750 mg/die + Sorafenib 200 mg bid
- Lapatinib and Sorafenib 2° level of dose (Type: EXPERIMENTAL): 2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
- Lapatinib and Sorafenib 3° level of dose (Type: EXPERIMENTAL): 3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
- Lapatinib and Sorafenib 4° level of dose (Type: EXPERIMENTAL): 4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 6 to 59 months~* Weight Greater than or equal to 5 kg~* Absence of severe malnutrition;~* Mono-infection with Plasmodium falciparum in blood, confirmed by microscopy;~* Parasite density between 2,000 and 200,000 asexual parasites per microliter of blood;~* Axillary temperature ≥ 37.5 C° or history of fever in the last 24 hours;~* Lack of danger signs, or no signs of severe and / or complicated malaria according to the WHO definition~* Ability to swallow the drugs~* Haemoglobin greater than 5.0 g / dl~* Residents within the study area and have the possibility of an adequate follow-up in the days of monitoring for a period of 28 days;~* Absence of a history of hypersensitivity to study medications;~* Informed consent of parents, guardians or caregivers (legal guardian) after explaining the purpose of the study.~Exclusion Criteria:~* Presence of any danger sign or severe or complicated Plasmodium falciparum malaria according to WHO definitions~* Presence of fever due to diseases other than malaria (eg measles, acute respiratory infection, severe diarrhea with dehydration) or other known diseases, with chronic or serious illnesses (cardiac, renal, hepatic or known infection with HIV AIDS),~* Presence of severe malnutrition (defined as a child whose growth pattern is below the 3rd percentile, mid-upper-arm circumference \<110mm, weight / height \<70% according to the WHO tables, or the presence of bilateral edema of the lower limbs)~* Multi or mono-infection by another Plasmodium species detected by microscopy;~* Regular medication that may interfere with the pharmacokinetics of antimalarials;~* History of hypersensitivity or contraindication to study drug;~* A history of taking antimalarial drugs or drugs with antimalarial activity in less than 7 days.~* Continuous prophylaxis with cotrimoxazole in HIV positive children

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Artemether-Lumefantrine (Type: ACTIVE_COMPARATOR): 4 sites, namely Massinga, Mopeia, Moatize and Montepuez
- Amodiaquine-Artesunate (Type: ACTIVE_COMPARATOR): 3 sites, namely Massinga, Mopeia and Montepuez

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Methylnaltrexone (MNTX) for the Relief of Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* Negative pregnancy test (serum or urine) at screening for all women of childbearing potential~* Advanced Medical Illness (i.e., terminal illness, such as incurable cancer or end of stage AIDS) with life expectancy of ≥ 1 month~* patient must sign ICF~Exclusion Criteria:~* Women who are pregnant and/or nursing~* Previous treatment with MNTX~* Participation in any other studies involving investigational products within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had an ischemic stroke believed to be due to small vessel disease, large vessel cervical or intracranial atherosclerosis within the past 10 days~* Subject is willing and able to undergo study requirements and expected to be geographically stable during study follow-up~* Subject is 60 years of age or older, or age 50 to 59 years plus a documented medical history of at least one of the following additional risk factors for stroke:~  * Congestive heart failure~ * Hypertension (Systolic Blood Pressure \> 140)~ * Diabetes Mellitus~ * Prior Stroke (\>90 days ago, other than study qualifying index event)~ * Vascular disease (e.g. coronary artery disease, heart attack, peripheral artery disease and complex aortic plaque)~Exclusion Criteria:~* Subject has had a cryptogenic stroke~* Subject has had a cardioembolic stroke~* Subject has untreated hyperthyroidism~* Subject has had a recent myocardial infarction \<1 month of stroke~* Subject has had a recent cardiac surgery (e.g. coronary artery bypass surgery (CABG)) \<1 month of stroke~* Subject has a mechanical heart valve~* Subject has valvular disease requiring immediate surgical intervention~* Subject has documented prior history of atrial fibrillation or atrial flutter~* Subject has permanent indication for oral anticoagulation~* Subject has permanent contraindication to oral anticoagulation such that detection of AF would not change medical management, based on enrolling investigators judgment~* Subject is enrolled in a concurrent study that may confound the results of this study. Co-enrollment in any concurrent clinical study (including registries) requires approval of the study manager or designee.~* Subject's life expectancy is less than 1 year~* Subject is pregnant~* Subject has or is indicated for implant with a pacemaker, Implantable Cardioverter Defibrillator (ICD), Cardiac ResynchronizationTherapy (CRT), or an implantable hemodynamic monitor~* Subject with a medical condition that precludes the patient from participation in the opinion of the investigator

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reveal LINQ™ Insertable Cardiac Monitor (Type: ACTIVE_COMPARATOR): Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
- Control Arm (Type: NO_INTERVENTION): Subjects randomized to the control arm will be followed per site specific standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults over 20 years~* taking the lumbar spinal surgery : single-level, posterior fusion~* stay in hospital more than 2 days after operation~Exclusion Criteria:~* pregnancy or breast-feeding~* allergy or contraindication to buprenorphine~* patient with decreased lung function~* patient with taking MAO inhibitor or anticonvulsant~* patient with brain lesion, or severe liver disease~* dependence in opioid drugs~* taking muscle relaxant or tranquilizer~* patient had taken buprenorphine preoperatively~* taking strong opioids before enrolling the study~* another severe source of pain except lumbar spine~* severe cardiovascular, pulmonary, or renal compromised patients

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Buprenorphine (Type: EXPERIMENTAL): Buprenorphine group : They will apply 3 days after the spine operation.
- Tramadol (Type: ACTIVE_COMPARATOR): Tramadol group : They will take a pill of tramadol analgesics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical definite Multiple Sclerosis diagnosis according to the McDonald criteria~* About to commence alemtuzumab (Lemtrada) treatment~* Expanded Disability Status Scale (EDSS) ≤ 5.5~* Signed informed consent~Exclusion Criteria:~* Co-morbidities that prevent participation in the project (dementia, serious cognitive disorders etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Informed Consent in Pediatric Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parent of child undergoing 1st, elective, outpatient, sedated, upper endoscopy (EGD)~* Subject gives consent to participate~* Child of parent does not have a planned endoscopy intervention.~Exclusion Criteria:~* Does not speak or understand English~* Does not give consent to participate~* Does not complete consent instrument at a minimum during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Electronic Assisted Consent (Type: EXPERIMENTAL): Standard procedural consent performed by pediatric gastroenterologist plus assistance from computerized emmi module.
- Control Consent (Type: NO_INTERVENTION): Standard procedural consent as performed by pediatric gastroenterologists

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed CF diagnosis by two positive chloride sweat tests or gene analysis~* Confirmed PEI by historical Coefficient of fat Absorption \< 70% without supplementation or current or historical fecal elastase \< 50µg/stool (within the last 12 months)~* Currently receiving treatment with a commercially available pancreatic enzyme product on a stable dose for more than 3 months~* Clinically stable condition without evidence of acute respiratory disease or any other acute condition~* Stable body weight and agrees to abstain from sexual activity~Exclusion Criteria:~* Ileus or acute abdomen~* History of fibrosing colonopathy, celiac disease, gastrectomy, Crohn´s disease and small bowel surgery other than minor resection due to meconium ileus without resulting in malabsorption syndrome~* History of distal ileal obstruction syndrome within 6 months of enrollment~* Use of an immunosuppressive drug~* Any type of malignancy involving the digestive tract in the last 5 years~* Known infection with HIV

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete